Grey Matter Damage at the Earliest Phase of Multiple Sclerosis : a Longitudinal 7T MRI Study
NCT ID: NCT03659981
Last Updated: 2024-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
32 participants
INTERVENTIONAL
2018-12-20
2026-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
NCT03624296
MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis
NCT03356366
MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis
NCT05491031
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
NCT03872583
Risk Factors in Early Multiple Sclerosis
NCT03586986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MS Patients
Multiple sclerosis patients MRI 7T will be performed
MRI 7T
The imaging parameters will come from the 7 Tesla Siemens MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI 7T
The imaging parameters will come from the 7 Tesla Siemens MRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Oligoclonal bands on CSF analysis
* Age between 18 and 45
* No previous history of neurological symptoms suggestive of demyelination
* No steroids in the month before MRI
* First MRI within six months after the first clinical episode
Exclusion Criteria
* Previous history of neurological or psychiatric disease
* Previous administration of immunosuppressive drugs
* Pregnancy
* Patient unable to give his consent for the study or patient under tutorship
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EMILIE GARRIDO PRADALIE
Role: STUDY_DIRECTOR
APHM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique Des Hopitaux de Marseille
Marseille, PACA, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.